<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034851</url>
  </required_header>
  <id_info>
    <org_study_id>IISPV_Pediatria_Dexcar</org_study_id>
    <secondary_id>2011-005805-66</secondary_id>
    <nct_id>NCT02034851</nct_id>
  </id_info>
  <brief_title>Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection</brief_title>
  <acronym>DEXCAR-0212</acronym>
  <official_title>Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Investigacio Sanitaria Pere Virgili</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitari Sant Joan de Reus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Joan XXIII de Tarragona.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pius Hospital de Valls</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maternal-Infantil Vall d´Hebron Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General Universitario Santa Lucía</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Rovira i Virgili</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Investigacio Sanitaria Pere Virgili</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: Administration of corticoids (dexamethasone) together with the conventional&#xD;
      antibiotherapy in the acute phase of a febrile urinary tract infection could reduce the risk&#xD;
      of renal scarring after 6 months of the primo-infection.&#xD;
&#xD;
      Primary objectives:To evaluate the reduction in incidence of renal scarring after 6 months of&#xD;
      a acute pyelonephritis between the control group (conventional therapy plus placebo) and&#xD;
      intervention group (conventional therapy plus dexamethasone.&#xD;
&#xD;
      Design: Multicentre randomized clinical trial,placebo controled, including children between 2&#xD;
      months and 14 years with a acute pyelonephritis proven by a acute phase DMSA&#xD;
      (dimethylsuccinic acid ). A total of 180 children in to parallel groups (intervention and&#xD;
      placebo) will be included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The urinary tract infection (UTI) is one of the most common bacterial infections in children.&#xD;
      These infections can be grouped clinically as asymptomatic bacteriuria , cystitis (lower&#xD;
      urinary tract infection ) and acute pyelonephritis (APN ) when the infection reaches the&#xD;
      upper urinary tract. This classification is of great clinical relevance because while&#xD;
      cystitis is usually a benign condition without further complications , the APN is associated&#xD;
      with an increased risk of kidney damage, acquired through renal scarring . Renal scarring is&#xD;
      a consequence of the inflammatory and immune response that is triggered to eradicate the&#xD;
      bacteria involved in the UTI. Parenchymal infection can be solved , but there are a number of&#xD;
      poorly understood factors that may perpetuate inflammation and this would promote the&#xD;
      formation of scar nephritis. One of the most relevant factors involved in the renal scarring&#xD;
      development are the production of inflammatory mediators (complement proteins, bactericidal&#xD;
      peptides, cytokines such as IL6 and IL8, chemokines, and adhesion molecules defensins). Thus,&#xD;
      it is obvious to think that the use of anti-inflammatory drugs may prevent the release of&#xD;
      these mediators and the development of permanent kidney damage.&#xD;
&#xD;
      Intervention: the two parallel groups will receive the conventional therapy plus:&#xD;
&#xD;
        1. dexamethasone: 0'30 mg per kg every 12 hours during 3 days.&#xD;
&#xD;
        2. placebo (physiological saline)at the same dosing regimen.&#xD;
&#xD;
      Centralized lecture of the late DMSA after 6 months of the pyelonephritis episode will be&#xD;
      performed. Renal scarring presence and grade will be reported.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>renal scarring</measure>
    <time_frame>6 month after the acute pyelonephritis episode</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">183</enrollment>
  <condition>Acute Pyelonephritis</condition>
  <arm_group>
    <arm_group_label>Dexamethasone</arm_group_label>
    <description>Intervention group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Placebo group (physiological saline)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Those children between 2 months and 14 years with a provable acute pyelonephritis that&#xD;
        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Those children between 2 months and 14 years with a provable acute pyelonephritis that&#xD;
        fulfill the hospitalization criteria defined in the Spanish Clinical practice guide.&#xD;
        Briefly:&#xD;
&#xD;
          -  age under 3 months.&#xD;
&#xD;
          -  general affectation, toxic appearance.&#xD;
&#xD;
          -  vomiting or oral intolerance.&#xD;
&#xD;
          -  dehydration, bad peripheric perfusion.&#xD;
&#xD;
          -  or other intermedia situations that include:&#xD;
&#xD;
               1. high fever (&gt;38.5 Celsius) in 3-6 month old children.&#xD;
&#xD;
               2. unusual germ risk factors.&#xD;
&#xD;
               3. family history of vesicoureteral reflux.&#xD;
&#xD;
               4. recurrent febrile urinary infections. With absence of a previous renal scarring&#xD;
                  objectivated after a DMSA.&#xD;
&#xD;
               5. high elevation of acute phase reactants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  those eligible patients that do not fulfill the hospitalization criteria.&#xD;
&#xD;
          -  patients with a procalcitonin under 0.05 ng per ml.&#xD;
&#xD;
          -  patients with previous uropathy or renal scarring&#xD;
&#xD;
          -  patients allergic to dexamethasone.&#xD;
&#xD;
          -  endocrinologic disease.&#xD;
&#xD;
          -  history of cancer.&#xD;
&#xD;
          -  serious illness.&#xD;
&#xD;
          -  immunosuppressor treatment.&#xD;
&#xD;
          -  previous treatment with corticoids (continuous oral or parenteral treatment) during&#xD;
             the last 2 months.&#xD;
&#xD;
          -  the patient included in the study that do not present pyelonephritis after the acute&#xD;
             phase DMSA evaluation will be excluded.&#xD;
&#xD;
          -  the patient included in the study that suffered a second pyelonephritis episode during&#xD;
             the following 6 months (before the second DMSA evaluation) will be excluded for the&#xD;
             primary output analyses.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Escribano J Joaquin, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IISPV- URV-Hospital Universitari Sant Joan de Reus- Research unit in pediatrics, nutrition and human development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Closa R Ricardo, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IISPV-URV- Hospital Universitari Joan XXIII de Tarragona-Research unit in pediatrics, nutrition and human development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferré N Natalia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IISPV-URV-Research unit in pediatrics, nutrition and human development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibars Z Zaira, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL ARNAU DE VILANOVA DE LLEIDA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Gloria MG Fraga, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL DE LA SANTA CREU I SANT PAU, DE BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Madrid A Alvaro, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL MATERNOINFANTIL VALL D'HBRON, BARCELONA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samper M Manuel, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pius Hospital de Valls</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gonzalez JD Juan David, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL GENERAL UNIVERSITARIO SANTA LUCÍA DE CARTAGENA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Parada E Esther, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>HOSPITAL JOAN XXII DE TARRAGONA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital General Universitario Santa Lucía de Cartagena</name>
      <address>
        <city>Cartagena</city>
        <state>Murica</state>
        <zip>E30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iispv- Hospital Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>E43204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pius Hospital de Valls</name>
      <address>
        <city>Valls</city>
        <state>Tarragona</state>
        <zip>E43800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Maternoinfantil Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>E08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de La Santa Creu I Sant Pau de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>E08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>E25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iispv-Hospital Joan Xxii de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <zip>E43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>January 10, 2014</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute pyelonephritis</keyword>
  <keyword>Renal scarring</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Children</keyword>
  <keyword>Corticoids</keyword>
  <keyword>Complementary treatment</keyword>
  <keyword>Prevention strategy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Pyelonephritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

